A dihydroxymethyl propionic acid ester of rapamycin with improved solubility that specifically inhibits mTOR signaling with a potency similar to that of rapamycin; demonstrates cytostatic activity in various mouse models of human tumors, including glioblastomas, prostate carcinoma, pancreatic, liver, breast cancers, and medulloblastoma.